Abstract 1
Objectives Until recently, randomized controlled trials and meta-analyses have not 2 demonstrated convincing conclusions regarding the association of calcium intake with 3 bone mineral density (BMD) . Until now, it remains unclear whether high serum calcium 4 levels are causally associated with BMD. This study aimed to investigate the genetic 5 association between serum calcium levels and BMD using a large-scale serum calcium 6 GWAS dataset and four large-scale BMD GWAS datasets in individuals of European 7 descent. 8 9 Methods We performed a Mendelian randomization study to investigate the association 10 of increased serum calcium levels with BMD using a large-scale serum calcium 11 genome-wide association study (GWAS) dataset (including up to 61,079 individuals) and 12 four large-scale BMD GWAS datasets (including minimum 4,180 individuals and 13 maximum 142,487 individuals) regarding the total body, forearm, femoral neck, lumbar 14 spine, and heel BMD. Here, we selected three Mendelian randomization methods 15 including inverse-variance weighted meta-analysis (IVW), weighted median, and 16 MR-Egger. 17 18 Results In specific site analysis, we found that increased serum calcium levels could 19 reduce BMD at forearm (OR=0.59, 95% CI: 0.36-0.95, P=0.029) and lumbar spine 20 (OR=0.65, 95% CI: 0.49-0.86, P=0.002). We did not identify any suggestive association 21 of genetically increased serum calcium levels with BMD of total body, femoral neck, and 22 heel BMD. In specific age stratum analysis, we found that genetically increased serum 23 calcium levels were statistically significantly associated with reduced total body BMD in 24 age stratum 60 or more years (OR=0.58, 95% CI: 0.41-0.82, P=0.002). 25 26 Conclusions We provide genetic evidence that increased serum calcium levels could not 27 improve BMD in the general population. The elevated serum calcium levels in generally 28 healthy populations, especially adults older than 60 years, may even reduce the BMD, 29 and further cause osteoporosis. 30 31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50 Introduction 1 Calcium is involved in many biological processes [1] . It is well known that calcium 2 deficiency could cause osteoporosis [2] . Osteoporosis is a common systemic skeletal 3 disease characterized by an increased propensity to fracture [2] . Osteoporosis could be 4 diagnosed mainly through measurement of bone mineral density (BMD) [2] . Until now, 5 randomized controlled trials and meta-analyses have not demonstrated convincing 6 evidence that calcium intake (diet and supplements) could improve BMD. In fact, 7 meta-analyses published to date have reported inconsistent conclusions regarding the 8 association of calcium intake with BMD [3]. In 2015, Tai et al. performed a systematic 9 review and meta-analysis of 59 randomized controlled trials [3] . They found that the 10 increasing calcium intake from diet or supplements could produce small non-progressive 11 increases in BMD, which are unlikely to lead to a clinically significant reduction in risk 12 of fracture [3] . 13 In addition to BMD, randomized controlled trials and meta-analyses published to date . 21 They found that dietary calcium intake was not associated with risk of fracture. 22 Meanwhile, no clinical trial evidence shows that increasing dietary calcium intake could 23 prevent risk of fracture [5] . There is weak and inconsistent evidence that calcium The Mendelian randomization is based on three principal assumptions, which have been 44 widely described in recent studies [1, 15] . First, the genetic variants selected to be 45 instrumental variables should be associated with the exposure (serum calcium levels) 46 (assumption 1) [1, 15] . Second, the genetic variants should not be associated with 47 confounders (assumption 2) [1, 15] . Third, genetic variants should affect the risk of the 48 outcome (BMD) only through the exposure (serum calcium levels) (assumption 3) [1, 15] . 49 The second and third assumptions are collectively known as independence from 50 pleiotropy [15] . This study is based on the publicly available, large-scale GWAS 1 summary datasets. All participants gave informed consent in all these corresponding 2 original studies. The discovery stage and the meta-analysis of the discovery and replication stage 10 identified 8 genetic variants to be associated with serum calcium levels with the 11 genome-wide significance (P < 5.00E-08) [10]. All these 8 genetic variants were located 12 in different genes and were not in linkage disequilibrium (Table 1) [10]. We provided 13 more detailed information including the methods to measure serum calcium levels in 14 eTable 1. Table 1 17 18 
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BMD GWAS Datasets
Pleiotropy Analysis
32
In Mendelian randomization study, one important issue is potential violation of 33 assumption 2 and 3 through pleiotropy occurring when a genetic instrument is associated 34 with a study outcome through biological pathways outside the exposure of interest. Here, 35 we performed an assessment for pleiotropy to assure that the selected genetic variants do 36 not exert effects on BMD through biological pathways independent of serum calcium 37 levels. We have provided more detailed information in eMethods.
39
Mendelian Randomization Analysis 40 Here, we selected the inverse-variance weighted meta-analysis (IVW) as the main 41 analysis method. In addition, we selected the weighted median regression and MR-Egger 42 regression as the sensitivity analysis methods. The selection of multiple Mendelian 43 randomization methods could examine the robustness of the estimate with each other. 44 These methods have widely used in previous studies [1, [12] [13] [14] [15] [16] [17] 19] . 45 In order to further assess the robustness of the genetic estimates, we conducted a Of these 8 genetic variants associated with serum calcium levels, we successfully 10 extracted the summary statistics for all these 8 genetic variants in each of these 10 GWAS 11 datasets, respectively. Some of these 8 genetic variants were significantly associated with 12 BMD at the Bonferroni corrected significance threshold (P<0.05/8=0.0063) (eTable 13 2-11).
15
Pleiotropy analysis 16 In stage 1, rs780094 was significantly associated with known confounders at the 17 Bonferroni corrected significance threshold (P<0.05/8=0.0063), as described in eTable the Mendelian randomization assumptions, we excluded rs780094 variant in following 23 analysis. In stage 2, using the remaining 7 genetic variants, MR-Egger intercept test 24 showed no significant intercept (all P values > 0.05) in each of these 10 GWAS datasets 25 (Table 2) . Hence, our following analysis will be based on these 7 genetic variants.
27
Association of serum calcium with BMD 28 In the forearm BMD GWAS dataset, IVW showed suggestive association between 29 genetically increased serum calcium levels and reduced BMD (OR=0.59, 95% CI: P=0.002). In addition, weighted median showed suggestive association of genetically 36 increased serum calcium levels with reduced BMD (OR=0.65, 95% CI: 0.47-0.89, 37 P=0.007) ( Table 2) . We did not identify any suggestive association of genetically 38 increased serum calcium levels with femoral neck BMD, heel BMD, and total 39 body-BMD, as described in Table 2 . 40 In specific age stratum analysis, we identified no evidence of significant association of 41 serum calcium levels with total body-BMD in four age strata including 0-15 years, 15-30 42 years, 30-45 years, and 45-60 years. Only in age stratum 60 or more years, IVW showed 43 genetically increased serum calcium levels were statistically significantly associated with 44 reduced total body-BMD at a Bonferroni corrected significance P<0.05/10=0.005 45 (OR=0.58, 95% CI: 0.41-0.82, P=0.002). In addition, weighted median regression 46 showed suggestive association of genetically increased serum calcium levels with 47 reduced total body-BMD BMD (OR=0.64, 95% CI: 0.44-0.91, P=1.40E-02) ( Table 2) . 48 eFigure 1-10 show individual genetic estimates from each of the 7 genetic variants using 49 different methods. The leave-one-out permutation analysis further showed that the 50 6 direction and precision of the genetic estimates between increased serum calcium levels 1 and BMD remained largely unchanged using these methods. . 18 Hence, Mendelian randomization could avoid some limitations of observational studies, 19 and could be used to determine the causal inferences [1, [12] [13] [14] [15] [16] . Until now, the existing 20 large-scale serum calcium and BMD GWAS datasets prompts us to investigate the 21 potential genetic association between serum calcium and BMD by a Mendelian 22 randomization using a large-scale serum calcium GWAS dataset and four large-scale 23 BMD GWAS datasets. 24 Here, we evaluated the association of genetically increased serum calcium levels with 25 BMD of total body and specific sites including forearm, femoral neck, lumbar spine, and 26 heel in individuals mainly of European ancestry. The results showed that genetically 27 increased serum calcium levels could reduce BMD at forearm and lumbar spine, but 28 showed no association with BMD of total body, femoral neck and heel ( Table 2) . In 29 specific age stratum analysis, our findings indicated that genetically increased serum 30 calcium levels could only significantly reduce total body-BMD in age stratum 60 or more 31 years in the general population. It is worth mentioning that the serum calcium levels were 32 observed by the population-based studies including up to 61079 individuals of European 33 descent [10]. Therefore, our conclusions reflect the effects of serum calcium levels in the 34 general population. These conclusions may be applicable to noninstitutionalized or 35 community-dwelling asymptomatic adults without a history of fractures. However, these 36 conclusions may be not applicable to patients with osteoporosis, or a history of fractures, 37 or poor serum calcium intake. 38 In brief, randomized controlled trials usually enrolled adults who received calcium 39 supplementation and a concurrent comparison group that did not receive this intervention. 40 However, randomized controlled trials did not regularly screen for the individual serum 41 calcium status. It means that the selected individuals may have normal serum calcium 42 levels in the beginning of the trials, or after a short time calcium supplementation. 43 However, these individuals are still directly given a general recommendation to increase 44 calcium supplementation. If elevated serum calcium levels are causally associated with 45 reduced BMD in the generally healthy population, long time calcium supplementation in 46 these individuals could not improve BMD, but even reduce the BMD, and may further 47 cause osteoporosis. This may explain why randomized controlled trials and meta-analyses 48 have not demonstrated convincing evidence that calcium intake (both diet and 49 supplements) could improve BMD, and further lead to a clinically significant reduction in 50 risk of fracture [3-6]. 1 It is recommended that the daily calcium intake is 1000 to 1200 mg [21] . It is difficult to 2 get this recommended amount through diet alone, so calcium supplements are widely 3 used [21] . Until now, it remains unclear whether calcium intake from dietary sources has 4 health advantages over supplements [22] . In the United States, about 43% of people, 5 including about 70% of older women, take calcium supplements [23] . Hence, with the 6 widespread use of calcium supplements, the genetic association between increased serum 7 calcium levels and reduced BMD may have clinical and public health implications. 8 Our findings show that high serum calcium levels are not always better. We provide 9 genetic evidence that high serum calcium levels could reduce BMD in the general 10 population. If elevated serum calcium levels are causally associated with the reduced 11 BMD in the generally healthy population, then long time calcium supplementation could 12 not improve BMD. Therefore, our findings may explain why randomized controlled trials 13 have not achieved convincing evidence that calcium supplements could improve BMD. . 34 This Mendelian randomization study may also have several limitations. First, we 35 provided genetic evidence that genetically increased serum calcium levels could not 36 improve BMD, but even reduce BMD in the general population. In order to translate 37 these genetic findings into clinical and public health implications, the potential 38 mechanisms underlying this genetic association remain to be thoroughly evaluated. 39 Second, we still could not completely rule out that there may be additional confounders. 40 Until now, it is almost impossible to fully rule out pleiotropy present in any Mendelian 41 randomization study [1, 15, 25] . Third, the GWAS dataset of serum calcium levels is 42 from 61079 individuals of European descent [10]. We selected four BMD GWAS datasets 43 in individuals of European ancestry to reduce the effect of population stratification [18] . 44 In total body-BMD GWAS, most participants are from population-based cohorts of 45 European ancestry (86%), two cohorts comprised African American individuals (2%), 46 and four other studies included individuals with admixed background (14%) 11 . In the 47 original study, Medina-Gomez et al. used the LD score regression to rule out residual 48 population stratification or cryptic relatedness 11 . However, it could not be completely 49 ruled out that population stratification may have had some influence on the estimate. 50 Fourth, the genetic association between serum calcium levels and BMD may differ by 1 ethnicity or genetic ancestry. This genetic association should be further evaluated in other 2 ancestries. Hence, we will further improve our work in future. Fifth, the association of 3 serum calcium levels with additional outcomes, more clinically related, like osteoporosis 4 and fracture could also be interesting. However, we have no access to these datasets. 5 When these datasets are publicly available, we will further verify our findings. 6 In summary, we provide genetic evidence that increased serum calcium levels could not 7 improve BMD in the general population. The lifelong elevated serum calcium levels in 8 the generally healthy populations may even reduce the BMD. Competing financial interests 28 The authors declare no competing financial interests. * The significance of suggestive association between serum calcium levels and BMD was at P < 0.05.
